NVAX

Companies
NASDAQ
Novavax Inc.
Health Care
Price Chart
Overview

About NVAX

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.

Market Cap
$2.7B
Volume
37.5M
Avg. Volume
31.0M
P/E Ratio
-39.4375
Dividend Yield
0.00%
Employees
1.7K

Company Information

Exchange
NASDAQ
Sector
Health Care
Industry
Biotechnology
Risk & Correlation Analysis
Market Correlation
1.67
High Correlation
Volatility
High (1.00)
Relative to market

Macro Factor Sensitivities

Interest Rates
Medium Sensitivity
Inflation
Medium Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Medium Sensitivity
Portfolio Impact
Forecasts & Predictions

Premium Forecasts

Get AI-powered price predictions, technical analysis, and market forecasts for NVAX.

1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential

Technical Analysis

Based on technical indicators and chart patterns, NVAX shows...

AI Sentiment Analysis

Market sentiment analysis indicates...

Key Statistics
Market Cap$2.7B
Volume37.5M
P/E Ratio-39.44
Dividend Yield0.00%
Important Dates
Next Dividend
May 10, 2019
Next Earnings
February 27, 2025

PortfolioPilot Analysis

Get AI-powered insights on how NVAX fits into your investment strategy and portfolio diversification.

Pricing info last updated June 17, 2025 (after market close)Other info last updated April 2, 2025